Intratumoral Cancer Therapies Market Report 2026

Intratumoral Cancer Therapies Market Overview

• Intratumoral Cancer Therapies market size has reached to $156.96 billion in 2025 • Expected to grow to $274.76 billion in 2030 at a compound annual growth rate (CAGR) of 12% • Growth Driver: Rising Cancer Incidence Fuels Expansion Of Intratumoral Cancer Therapies Market • Market Trend: Technological Advancements Propel Intratumoral Cancer Therapies Market Growth • North America was the largest region in 2025.

What Is Covered Under Intratumoral Cancer Therapies Market?

Intratumoral cancer therapies refer to treatments that are directly injected or applied to a tumor. These therapies are specifically designed to target tumor cells and can be used with other cancer treatments, such as chemotherapy and radiation therapy. The main types of intratumoral cancer therapies are monoclonal antibodies, vaccines, checkpoint inhibitors, cell therapies, immune system modulators, adoptive cell transfer, and cytokines. Monoclonal antibodies refer to the particular kind of lab-made protein that can connect to certain bodily targets, including antigens found on the exterior of cancer cells. These are used in various applications such as lung cancer, breast cancer, melanoma, prostate cancer, head and neck cancer, and other applications, and are used by various end users such as hospitals, cancer research centers, and clinics.

What Is The Intratumoral Cancer Therapies Market Growth Forecast?

The intratumoral cancer therapies market size is expected to see rapid growth in the next few years. It will grow to $274.76 billion in 2030 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to rise in precision medicine adoption, growing use of immuno-oncology therapies, technological advances in injection devices, increasing collaboration with biotech firms, expanding cancer research funding. Major trends in the forecast period include targeted intratumoral drug delivery, combination therapy approaches, personalized cancer treatment, minimally invasive administration techniques, enhanced tumor microenvironment modulation.

Global Intratumoral Cancer Therapies Market Segmentation

1) By Technology: Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immunes System Modulator, Adoptive Cell Transfer, Cytokines 2) By Application: Lung Cancer, Breast Cancer, Melanoma, Prostate Cancer, Head And Neck Cancer, Other Applications 3) By End Users: Hospitals, Cancer Research Centers, Clinics Subsegments: 1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies 2) By Vaccines: Peptide-Based Vaccines, Protein-Based Vaccines, DNA Vaccines 3) By Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors, CTLA-4 Inhibitors 4) By Cell Therapies: CAR T-Cell Therapy, TCR Therapy 5) By Immune System Modulators: Immune Checkpoint Inhibitors, Toll-Like Receptor Agonists 6) By Adoptive Cell Transfer: Tumor-Infiltrating Lymphocytes (TILs), Peripheral Blood Lymphocytes (PBLs) 7) By Cytokines: Interleukins, Interferons, Tumor Necrosis Factor (TNF)

What Is The Driver Of The Intratumoral Cancer Therapies Market?

The increasing incidence of cancer is expected to propel the growth of the intratumoral cancer therapies market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. Intratumoral cancer therapies are used in diagnosing and treating cancer and help in avoiding off-target toxicities, dose-limiting toxicities, and adverse effects due to immune stimulation for patients suffering from cancer. For instance, in January 2023, the American Cancer Society, a U.S.-based nonprofit cancer advocacy organization, projected approximately 1,958,310 new cancer diagnoses in 2023 in the United States, compared with about 1,918,160 new cases in 2022, representing a rise of approximately 2.1%. Therefore, the increasing incidence of cancer is driving the growth of the intratumoral cancer therapies industry.

Key Players In The Global Intratumoral Cancer Therapies Market

Major companies operating in the intratumoral cancer therapies market are Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Johnson & Johnson, Eli Lilly and Company, F. Hoffmann-la Roche, Takeda Pharmaceutical Company Ltd., GSK plc, Ziopharm Oncology Inc., Celldex Therapeutics Inc., Astellas Pharma Inc., Sirnaomics, Checkmate Pharmaceuticals Inc., Immunovative Therapies Ltd., Idera Pharmaceuticals Inc., Daiichi Sankyo, Philogen S.p.A., Apexigen Inc., Merck Group, OncoSec Medical Incorporated, DNAtrix, Istari Oncology Inc., Nanobiotix, Exicure Inc., Karyopharm Therapeutics Inc., Torigen Pharmaceuticals Inc.

Global Intratumoral Cancer Therapies Market Trends and Insights

Major companies operating in the intratumoral cancer therapies market are focusing on developing innovative solutions, such as advanced oncolytic virus platforms, to meet the rising demand for targeted tumor destruction, enhanced immune activation, and next-generation localized cancer therapies. Oncolytic virus therapies are engineered viral constructs designed to selectively replicate within tumor cells, causing direct tumor lysis while simultaneously stimulating systemic anti-tumor immunity, offering a more targeted and immune-potentiating alternative to traditional chemotherapy and radiation. For instance, in November 2024, Replimune Group, Inc., a U.S.-based clinical-stage biotechnology company, announced that its lead candidate RP1 (vusolimogene oderparepvec), an engineered herpes simplex virus armed with a fusogenic protein and GM-CSF, received Breakthrough Therapy Designation from the FDA, and its Biologics License Application was submitted under the Accelerated Approval pathway. This technology enables intratumoral delivery of an oncolytic virus that directly destroys tumor cells and amplifies systemic immune responses, representing a significant advancement in cancer treatment.

What Are Latest Mergers And Acquisitions In The Intratumoral Cancer Therapies Market?

In January 2023, AstraZeneca, a UK-based, science-driven biopharmaceutical firm that concentrates on the research, commercialization, and discovery of prescription drugs for oncology and rare diseases, acquired Neogene Therapeutics Inc., for $120 million. This acquisition will open up new avenues for AstraZeneca for the treatment of cancer. Neogene Therapeutics Inc. is a Netherlands-based biotechnology research company that delivers a customized treatment based on TCR genes that target neoantigens detected in the tumor of a specific patient.

Regional Insights

North America was the largest region in the intratumoral cancer therapies market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Intratumoral Cancer Therapies Market?

The intratumoral cancer therapies market consists of revenues earned by entities by chemotherapy, radiation therapy, immunotherapy, and targeted therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Intratumoral Cancer Therapies Market Report 2026?

The intratumoral cancer therapies market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the intratumoral cancer therapies industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.